mavyret
Generic: glecaprevir and pibrentasvir
Labeler: abbvie inc.Drug Facts
Product Profile
Brand Name
mavyret
Generic Name
glecaprevir and pibrentasvir
Labeler
abbvie inc.
Dosage Form
PELLET
Routes
Active Ingredients
glecaprevir 50 mg/1, pibrentasvir 20 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0074-2600
Product ID
0074-2600_2c392930-500d-4e9b-93ac-317c4d48251c
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA215110
Listing Expiration
2027-12-31
Marketing Start
2021-06-10
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
00742600
Hyphenated Format
0074-2600
Supplemental Identifiers
RxCUI
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
mavyret (source: ndc)
Generic Name
glecaprevir and pibrentasvir (source: ndc)
Application Number
NDA215110 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 50 mg/1
- 20 mg/1
Packaging
- 1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET
Packages (1)
Ingredients (2)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "2c392930-500d-4e9b-93ac-317c4d48251c", "openfda": {"nui": ["N0000182639", "N0000182638", "N0000185503", "N0000190113", "N0000190107", "N0000190108", "N0000190114", "N0000182138", "N0000191272", "N0000191256"], "unii": ["K6BUU8J72P", "2WU922TK3L"], "rxcui": ["1940703", "1940709", "2557906", "2557910"], "spl_set_id": ["7bf99777-0401-9095-8645-16c6e907fcc0"], "pharm_class_epc": ["Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]", "Hepatitis C Virus NS5A Inhibitor [EPC]"], "pharm_class_moa": ["HCV NS3/4A Protease Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 1A2 Inhibitors [MoA]", "UGT1A1 Inhibitors [MoA]"], "manufacturer_name": ["AbbVie Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET", "package_ndc": "0074-2600-28", "marketing_start_date": "20210622"}], "brand_name": "Mavyret", "product_id": "0074-2600_2c392930-500d-4e9b-93ac-317c4d48251c", "dosage_form": "PELLET", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 1A2 Inhibitors [MoA]", "Cytochrome P450 1A2 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]", "Hepatitis C Virus NS5A Inhibitor [EPC]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "UGT1A1 Inhibitors [MoA]", "UGT1A1 Inhibitors [MoA]"], "product_ndc": "0074-2600", "generic_name": "Glecaprevir and Pibrentasvir", "labeler_name": "AbbVie Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Mavyret", "active_ingredients": [{"name": "GLECAPREVIR", "strength": "50 mg/1"}, {"name": "PIBRENTASVIR", "strength": "20 mg/1"}], "application_number": "NDA215110", "marketing_category": "NDA", "marketing_start_date": "20210610", "listing_expiration_date": "20271231"}